Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1993 2
1996 1
1998 1
1999 1
2002 1
2003 2
2004 2
2006 1
2007 1
2008 1
2009 4
2010 4
2011 2
2012 5
2013 3
2014 9
2015 21
2016 13
2017 14
2018 24
2019 24
2020 9
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 31420504

122 results
Results by year
Filters applied: . Clear all
Page 1
Points to Consider: Best Practices to Identify Particle Entry Routes along the Manufacturing Process for Parenteral Formulations.
Anger S, Begat C, Crnko V, Fantozzi G, Farach W, Fitzpatrick S, Gallagher B, Huelsmann S, Kinsey P, Langlade V, Lefevre G, Legendre E, McLean K, Miller J, Patel R, Perry A, Soukiassian H, Stanton A, Streich D, Timmons C, Vaneylen D, van Hoose T, Wildling L, Windover M. Anger S, et al. PDA J Pharm Sci Technol. 2019 Nov-Dec;73(6):635-647. doi: 10.5731/pdajpst.2019.010645. Epub 2019 Aug 16. PDA J Pharm Sci Technol. 2019. PMID: 31420504
Analysis of Particulate Matter in Liquid-Finished Dosage Forms.
Duchek J, Havasi B. Duchek J, et al. PDA J Pharm Sci Technol. 2018 Nov-Dec;72(6):608-625. doi: 10.5731/pdajpst.2017.008292. Epub 2018 May 31. PDA J Pharm Sci Technol. 2018. PMID: 29853612 Review.
Achieving "Zero" Defects for Visible Particles in Injectables.
Johns J, Golfetto P, Bush T, Fantozzi G, Shabushnig J, Perry A, Degrazio F, Streich D, Miller J, Soukiassian H, Stanton A, Watson R. Johns J, et al. PDA J Pharm Sci Technol. 2018 Nov-Dec;72(6):640-650. doi: 10.5731/pdajpst.2018.009027. Epub 2018 Sep 19. PDA J Pharm Sci Technol. 2018. PMID: 30232141
Conducting Clinical Risk Assessments for Visible Particulate Matter in Parenteral Preparations.
Ayres JD. Ayres JD. PDA J Pharm Sci Technol. 2018 Nov-Dec;72(6):626-639. doi: 10.5731/pdajpst.2018.008615. Epub 2018 Aug 29. PDA J Pharm Sci Technol. 2018. PMID: 30158238
Particulate Generation Mechanisms during Bulk Filling and Mitigation via New Glass Vial.
Timmons CL, Liu CY, Merkle S. Timmons CL, et al. PDA J Pharm Sci Technol. 2017 Sep-Oct;71(5):379-392. doi: 10.5731/pdajpst.2017.007724. Epub 2017 May 15. PDA J Pharm Sci Technol. 2017. PMID: 28512178
A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products.
Mathonet S, Mahler HC, Esswein ST, Mazaheri M, Cash PW, Wuchner K, Kallmeyer G, Das TK, Finkler C, Lennard A. Mathonet S, et al. PDA J Pharm Sci Technol. 2016 Jul-Aug;70(4):392-408. doi: 10.5731/pdajpst.2015.006189. Epub 2016 Apr 18. PDA J Pharm Sci Technol. 2016. PMID: 27091885 Review.
The scientific basis for visible particle inspection.
Knapp JZ. Knapp JZ. PDA J Pharm Sci Technol. 1999 Nov-Dec;53(6):291-302. PDA J Pharm Sci Technol. 1999. PMID: 10754727
Semi-Quantitative Analysis of Inherent Visible Particles for Biopharmaceutical Products.
Cash PW, Narwal R, Levitskaya SV, Krause S, Murphy D, Mazaheri M. Cash PW, et al. PDA J Pharm Sci Technol. 2016 Mar-Apr;70(2):134-42. doi: 10.5731/pdajpst.2015.006064. Epub 2016 Jan 21. PDA J Pharm Sci Technol. 2016. PMID: 26797974
A practical discussion of risk management for manufacturing of pharmaceutical products.
Mollah AH, Baseman HS, Long M, Rathore AS. Mollah AH, et al. PDA J Pharm Sci Technol. 2014 May-Jun;68(3):271-80. doi: 10.5731/pdajpst.2014.00975. PDA J Pharm Sci Technol. 2014. PMID: 25188348 Review.
Balancing Container Closure Integrity and Aesthetics for a Robust Aseptic or Sterile Vial Packaging System.
Oni Y, Song X, Schrader M, Kulshrestha A, Franck J, Asselta R, Flores-Crespo C, Mantri RV. Oni Y, et al. PDA J Pharm Sci Technol. 2019 Nov-Dec;73(6):572-587. doi: 10.5731/pdajpst.2018.009670. Epub 2019 May 17. PDA J Pharm Sci Technol. 2019. PMID: 31101708
122 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback